How effective is Gilenya for Multiple Sclerosis? (a real world drug study)
Summary:
Overall ratings: 3.2/5 Long term ratings: 3.5/5
This is a phase IV clinical study of how effective Gilenya (fingolimod) is for Multiple sclerosis and for what kind of people. The study is created by eHealthMe from 115 Gilenya users and is updated continuously.
What is Gilenya?
Gilenya has active ingredients of fingolimod. It is often used in multiple sclerosis. eHealthMe is studying from 111,893 Gilenya users. Check the latest studies of Gilenya.
What is Multiple sclerosis?
Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,085 drugs and 1,365 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
115 people are studied for taking Gilenya in Multiple sclerosis
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Gilenya effectiveness for Multiple sclerosis (number of people):
Overall:
- not at all: 6
- somewhat: 24
- moderate: 36
- high: 35
- very high: 14
Long Term:
- not at all: 0
- somewhat: 13
- moderate: 20
- high: 25
- very high: 12
Gender of people who take Gilenya for Multiple sclerosis *:
- female: 81.74 %
- male: 18.26 %
Age of people who take Gilenya for Multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 14.78 %
- 30-39: 26.96 %
- 40-49: 35.65 %
- 50-59: 18.26 %
- 60+: 4.35 %
Who find Gilenya more effective for Multiple Sclerosis?
Gender of people who take Gilenya for Multiple sclerosis *:
- female: 79.59 %
- male: 20.41 %
Age of people who take Gilenya for Multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 14.29 %
- 30-39: 24.49 %
- 40-49: 34.69 %
- 50-59: 18.37 %
- 60+: 8.16 %
* Approximation only. Some reports may have incomplete information.
Do you take Gilenya?
- You can start a phase IV clinical trial to monitor Gilenya safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Related studies
Alternative drugs to, pros and cons of:
- Gilenya (111,893 reports)
Treatments, associated drugs and conditions:
- Multiple sclerosis (799,637 reports)
How the study uses the data?
The study is based on fingolimod (the active ingredients of Gilenya) and Gilenya (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Lasix vs. Labetalol Hydrocloride, side effect and effectiveness comparison - now
- Could Femara cause Hepatic Cyst? - a second ago
- Could Prednisone cause Hyperuricaemia? - 4 seconds ago
- How effective is Levothroid for Chronic Thyroiditis? - 5 seconds ago
- Drug interactions of Fluticasone Propionate and Zometa - 8 seconds ago
- Septic Shock and drugs of ingredients of droxidopa - 9 seconds ago
- How effective is Celexa for Depressed Mood? - 11 seconds ago
- Weight Increased and drugs of ingredients of dandelion - 14 seconds ago
- Depression and Stress And Anxiety - 15 seconds ago
- Could Leukine cause Fever? - 15 seconds ago